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Abstract
Background—High-sensitivity cardiac troponin testing may improve the risk-stratification and 
diagnosis of myocardial infarction, but concentrations can be challenging to interpret in patients 
with renal impairment and the effectiveness of testing in this group is uncertain.
Methods—In a prospective multi-center study of consecutive patients with suspected acute 
coronary syndrome, we evaluated the performance of high-sensitivity cardiac troponin I in those 
with and without renal impairment (estimated glomerular filtration rate <60mL/min/1.73m2). The 
negative predictive value (NPV) and sensitivity of troponin concentrations below the risk 
stratification threshold (5ng/L) at presentation were reported for a primary outcome of index type 
1 myocardial infarction, or type 1 myocardial infarction or cardiac death at 30 days. The positive 
predictive value (PPV) and specificity at the 99th centile diagnostic threshold (16ng/L in women, 
34ng/L in men) was determined for index type 1 myocardial infarction. Subsequent type 1 
myocardial infarction and cardiac death were reported at 1 year.
Results—Of 4,726 patients identified, 904 (19%) had renal impairment. Troponin concentrations 
<5ng/L at presentation identified 17% of patients with renal impairment as low-risk for the 
primary outcome (NPV 98.4%, 95% confidence interval [CI] 96.0-99.7%; sensitivity 98.9%, 
95%CI 97.5-99.9%), compared to 56% without renal impairment (P<0.001) with similar 
performance (NPV 99.7%, 95%CI 99.4-99.9%; sensitivity 98.4%, 95%CI 97.2-99.4%). The PPV
and specificity at the 99th centile were lower in patients with renal impairment at 50.0% (95%CI 
45.2-54.8%) and 70.9% (95%CI 67.5-74.2%) respectively, compared to 62.4% (95%CI 58.8-
65.9%) and 92.1% (95%CI 91.2-93.0%) in those without. At 1 year, patients with troponin 
concentrations >99th centile and renal impairment were at greater risk of subsequent myocardial 
infarction or cardiac death than those with normal renal function (24% vs. 10%, adjusted hazard 
ratio 2.19, 95%CI 1.54-3.11). 
Conclusions—In suspected acute coronary syndrome, high-sensitivity cardiac troponin 
identified fewer patients with renal impairment as low-risk and more as high-risk, but with lower 
specificity for type 1 myocardial infarction. Irrespective of diagnosis, patients with renal 
impairment and elevated cardiac troponin concentrations had two-fold greater risk of a major
cardiac event compared to those with normal renal function, and should be considered for further 
investigation and treatment.
Clinical Trial Registration—URL: https://clinicaltrials.gov Unique Identifier: NCT01852123 
Key Words: renal disease; troponin; acute coronary syndrome 
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Clinical Perspective
What is new?
x This is the first study to evaluate high-sensitivity cardiac troponin I testing in unselected, 
consecutive patients with suspected acute coronary syndrome with and without renal 
impairment.
x Patients with troponin concentrations <5ng/L at presentation were low-risk for 
myocardial infarction or cardiac death regardless of renal function, but only one in five 
patients with renal impairment were identified as low-risk.  
x Patients with renal impairment were twice as likely to have troponin concentrations 
above the 99th centile, with lower specificity for type 1 myocardial infarction, but 
irrespective of the diagnosis these patients had a 2-fold greater risk of cardiac events at 1 
year. 
What are the clinical implications?
x Our findings support the use of high-sensitivity cardiac troponin I testing, using a risk 
stratification threshold of <5ng/L, to rule out myocardial infarction in patients with renal 
impairment. 
x The use of diagnostic thresholds above the 99th centile might improve specificity for type 
1 myocardial infarction in patients with renal impairment. 
x However, such strategies may falsely reassure clinicians that patients below this threshold 
are at low risk.
x High-sensitivity cardiac troponin I has major potential to risk stratify patients with renal 
impairment and suspected acute coronary syndrome.  
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Cardiovascular disease is the most frequent outcome of chronic kidney disease.1 As glomerular 
filtration rate (GFR) declines, major adverse cardiovascular events, cardiovascular and all-cause 
mortality increase.1-3 In patients with acute coronary syndrome, renal impairment is common4
and is associated with an increased risk of recurrent myocardial infarction and death.5, 6 Cardiac
troponin testing is used widely to diagnose myocardial infarction,7-10 however levels can be 
challenging to interpret in patients with renal impairment.11, 12 Circulating troponin 
concentrations are often raised in these patients due to shared risk factors and pre-existing 
cardiovascular disease.13 High-sensitivity cardiac troponin assays permit the use of lower 
thresholds to rule in and rule out myocardial infarction,14 but the effectiveness of testing in 
patients with renal impairment is uncertain.  
We have previously evaluated high-sensitivity cardiac troponin testing in consecutive 
patients with suspected acute coronary syndrome and defined thresholds for risk stratification 
(<5ng/L) and diagnosis of myocardial infarction using sex-specific 99th centile upper reference 
limits.7, 15 Patients with cardiac troponin concentrations <5ng/L at presentation were at low risk 
of future cardiac events and may not require serial testing or hospital admission.7, 16, 17 The use of 
sex-specific diagnostic thresholds identified more women with myocardial infarction who were 
at increased risk of major cardiac events.14 The benefits of both approaches may be offset in
patients with comorbid conditions and especially those with renal impairment, where myocardial 
injury often occurs outwith acute coronary syndrome, and where high-sensitivity cardiac 
troponin testing may contribute to diagnostic uncertainty. We aimed to evaluate the performance 
of high-sensitivity cardiac troponin I testing in consecutive patients with suspected acute 
coronary syndrome with and without renal impairment.
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Methods
Study design & participants
In a prospective multi-center study, we identified consecutive patients presenting with suspected 
acute coronary syndrome to the emergency departments of two secondary care hospitals (St 
John’s Hospital, Livingston and Western General Hospital, Edinburgh) and a tertiary care 
hospital (Royal Infirmary of Edinburgh) between June 1, 2013 and January 31, 2014.7 All 
patients in whom the attending clinician requested cardiac troponin for suspected acute coronary 
syndrome were enrolled. Patients were excluded if they were diagnosed with ST-segment 
elevation myocardial infarction, had been admitted previously during the study period or did not 
live in Scotland and therefore could not have hospital records linked with outcomes. In this 
analysis, we identified those patients who also had at least one measurement of serum creatinine 
during the index presentation. The study was approved by the national research ethics 
committee, and performed in accordance with the Declaration of Helsinki. Informed consent was 
not required. 
Procedures
Plasma cardiac troponin I concentration was measured at presentation and then repeated 6 or 12 
hours after the onset of symptoms at the discretion of the clinician. All patients who met the 
inclusion criteria were assigned a study code and additional data from the electronic patient 
record (TrakCare; InterSystems Corporation, Cambridge, MA, USA) were collected 
prospectively and linked in real time with a unique patient identifier.
Clinical decision-making utilized a validated standard-of-care sensitive cardiac troponin I 
assay (ARCHITECTSTAT troponin I assay; Abbott Laboratories, Abbott Park, IL, USA).18, 19
High-sensitivity cardiac troponin I was measured in parallel on excess plasma in all enrolled 
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patients, at all time points, using a high-sensitivity assay (ARCHITECTSTAT high-sensitive 
troponin I assay; Abbott Laboratories). These results were not reported on the electronic patient 
record or communicated to the clinicians responsible for patients’ care. For this assay, the limit 
of detection (LoD) is 1.2ng/L with an upper reference limit at the 99th centile in women of 
16ng/L and in men of 34ng/L.15, 20 It has a coefficient of variation of 23% at the limit of 
detection (1.2ng/L) and <10% at 6ng/L.7, 21, 22
Baseline clinical characteristics and serum biochemistry results were collected using the 
electronic patient record. Serum creatinine at presentation was used to calculate the estimated 
glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) study 
equation.23 Based on this, patients were classified as having ‘normal’ (eGFR 
60mL/min/1.73m2) or ‘impaired’ renal function (eGFR <60mL/min/1.73m2). Those with renal 
impairment were further categorized as having moderate (eGFR 30-59mL/min/1.73m2), severe 
(<30mL/min/1.73m2) or end-stage (<15 mL/min/1.73m2) renal disease.
Patients with evidence of myocardial necrosis at presentation or on subsequent testing 
were identified using sex-specific upper reference limits (troponin concentration >99th centile). 
When patients had serial samples tested, ‘peak troponin’ was defined as the highest cardiac 
troponin concentration obtained within 24 hours of hospital presentation. All investigations, 
clinical information and outcomes from presentation to 30 days were independently reviewed by 
two adjudicators (AS and AA). Patients were classified as having type 1 or type 2 myocardial 
infarction or myocardial injury, according to the Universal Definition of Myocardial Infarction
(Supplementary Table 1).11, 24 Type 1 myocardial infarction was defined in patients with 
myocardial necrosis and symptoms suggestive of acute coronary syndrome or evidence of 
myocardial ischemia on an electrocardiogram. Type 2 myocardial infarction was diagnosed in 
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those patients with symptoms or signs of myocardial ischemia due to increased oxygen demand 
or decreased supply (e.g. tachyarrhythmia, hypotension, or anemia). Myocardial injury was 
defined as biochemical evidence of myocardial necrosis in the absence of any clinical features of 
myocardial ischemia. Any discrepancies were resolved by the adjudication of a third independent 
reviewer (NLM). Index myocardial infarction was defined as any type 1 myocardial infarction 
arising during the first clinical episode. Agreement was good across all adjudicated diagnoses in 
patients with and without renal impairment ț72, 95% confidence interval (CI) 0.67–0.78 vsț
0.70, 95% CI 0.65–0.75). 
 Follow-up was completed using regional and national registries as well as the electronic 
patient record (TrakCare). The same adjudication process as the index admission was used to 
adjudicate any readmission with elevated cardiac troponin (>99th centile). Cardiac death was 
defined as any death due to myocardial infarction, arrhythmia, or heart failure.
Outcomes
The negative predictive value (NPV) and sensitivity of cardiac troponin concentrations below the 
risk stratification threshold (5ng/L) at presentation were reported for a primary outcome of index 
type 1 myocardial infarction, or type 1 myocardial infarction or cardiac death at 30 days, as 
previously described.7 We performed an additional sensitivity analysis evaluating the LoD as an 
alternative to this risk stratification threshold. The positive predictive value (PPV) and specificity
of cardiac troponin concentrations >99th centile (16ng/L in women, 34ng/L in men) on the 
presentation sample or subsequent testing was determined for index type 1 myocardial infarction. 
Sub-group analyses were performed stratified by age and sex. In those undergoing serial 
sampling, performance of the diagnostic threshold was evaluated at presentation and on repeat 
testing, with and without the inclusion of a 20% delta change in cardiac troponin concentration.25
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In a secondary analysis we evaluated the diagnostic performance for type 1 or type 2 myocardial 
infarction. Readmission with type 1 myocardial infarction, cardiac death and all cause death 
were reported at 1 year.
Statistical analysis 
Baseline characteristics across eGFR categories were presented as mean (SD) or median (IQR) 
for normally distributed and non-normally distributed variables respectively, and as proportions 
for categorical variables. A high-sensitivity cardiac troponin I concentration of <5ng/L at 
presentation conferred a NPV of 99.6% across the whole population for the primary outcome.7
This threshold was evaluated in those patients with normal and impaired renal function. As we 
expected the NPV to be close to 100%, we estimated the proportion by sampling from a binomial 
likelihood with a Jeffrey’s prior (beta distribution shape parameters both equal to 0.5) as 
intervals produced using this approach have good coverage for proportions close to 0 or 1.26
Survival free from type 1 myocardial infarction or cardiac death above and below the threshold 
of 5ng/L was compared. Multivariable cox proportional hazard models were performed to 
evaluate the association of eGFR and outcomes. Statistical analyses were performed using R, 
version 3.3.2.
Results
Patient characteristics
Of 4,739 patients enrolled, 4,726 patients (99.7%) had at least one measure of serum creatinine 
(Supplementary Figure 1). Of these, 904 patients (19%) had renal impairment with an eGFR 
<60mL/min/1.73m2 (Table 1). Most patients had moderate impairment (85%) with 15% having 
severe impairment (<30mL/min/1.73m2), and 13 (0.3%) patients receiving dialysis (12 on 
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hemodialysis, 1 on peritoneal dialysis) (Supplementary Table 2). Renal function was two-fold 
higher in those with normal renal function (eGFR 91±18 vs. 47±8mL/min/1.73m2, P<0.001).  
 Compared to patients with normal renal function, those with renal impairment were older 
and more likely to be female (Table 1). Baseline cardiovascular risk factors, including diabetes 
mellitus and hypertension, as well as established ischemic heart disease, were more prevalent in 
those with renal impairment. Prescriptions of anti-platelet agents, blockers of the renin-
angiotensin system and statins were more frequent in this group. However, smoking was less 
common. Although more patients with renal impairment had previously undergone coronary 
artery bypass grafting, the rate of percutaneous coronary intervention was similar to those with 
normal renal function.   
Renal impairment and risk stratification with low cardiac troponin concentrations at 
presentation
A cardiac troponin concentration of <5ng/L at presentation identified 17% (157/904) of patients 
with and 56% (2,144/3,822) of patients without renal impairment as low risk (Figure 1A). The 
primary outcome of index type 1 myocardial infarction, or type 1 myocardial infarction or 
cardiac death within 30 days occurred in 1% (2/157) of those with renal impairment and in 0.3% 
(7/2,144) of those with normal renal function. The NPV and sensitivity for the primary outcome 
was 98.4% (95% CI 96.0-99.7%) and 98.9% (95% CI 97.5-99.9%) in patients with renal 
impairment, compared to 99.7% (95% CI 99.4-99.9%) and 98.4 % (95% CI 97.2-99.4%) in those 
without (Table 2). Performance was similar when the primary outcome was extended to include 
all myocardial infarction (type 1 and type 2) (Supplementary Table 3). In our sensitivity 
analysis, the NPV and sensitivity at the LoD were similar to the risk stratification threshold, but 
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this threshold identified only 19/904 (2%) of patients with renal impairment as low risk, 
compared to 628/3,822 (16%) of those with normal renal function (Supplementary Table 4).
Renal impairment and the diagnosis of myocardial infarction 
Cardiac troponin concentrations were >99th centile at presentation in 40% (360/904) of patients 
with and 15% (578/3,822) without renal impairment (Figure 1A). During the index presentation, 
the adjudicated diagnosis was type 1 myocardial infarction in 23% (206/904) of patients with 
renal impairment compared to 12% (445/3,822) of those with normal renal function (Figure 1B). 
Similarly, an adjudicated diagnosis of type 2 myocardial infarction was more frequent in patients 
with renal impairment occurring in 7% (65/904), compared to 3% (108/3,822) of those with 
normal renal function. In those with renal impairment, the diagnosis of type 1 myocardial 
infarction occurred in 22% (167/765) of patients with moderate, 28% (29/102) with severe and 
27% (10/37) of patients with end-stage renal impairment. The diagnosis of type 2 myocardial 
infarction occurred in 7% (50/765) of patients with moderate, 10% (10/102) with severe and 
14% (5/37) of patients with end-stage renal impairment.
 At the 99th centile, the PPV and specificity for an index type 1 myocardial infarction were
lower in patients with renal impairment (50.0%, 95% CI 45.2-54.8% and 70.9%, 95% CI 67.5-
74.2%, respectively), compared to those without (62.4%, 95% CI 58.8-65.9% and 92.1%, 95% 
CI 91.2-93.0%, resepectively) (Table 2). The area under the curve for type 1 myocardial 
infarction was 0.95 (95% CI 0.93-0.96%) in patients without renal impairment compared to 0.82 
(95% CI 0.78-0.86%) in those with renal impairment. The PPV and specificity were similar in 
patients with renal impairment stratified by age or sex, but were lower in those >65 years old and 
in women without renal impairment (Supplementary Table 5). 
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 Sensitivity was similar in patients with and without renal impairment, both at 
presentation and on re-testing (Supplementary Table 5). In those patients with serial sampling
(2,193/4,726, 46%), combining the 99th centile with a 20% delta change increased specificity in 
those with renal impairment from 68.8% (95% CI 63.8-73.6%) to 78.1% (95% CI 73.6-82.4%), 
but reduced sensitivity from 97.8% (95% CI 95.5-99.7%) to 78.4% (95% CI 72.0-84.7%). In 
contrast, combining the 99th centile with a 20% delta change did not significantly improve 
specificity in patients without renal impairment (90.5%, 95% CI 88.9-92.1% with a delta versus
88.1%, 95% CI 86.4-89.8% without), but sensitivity was lower (81.8%, 95% CI 77.8-85.7% with 
a delta versus 98.5%, 95% CI 97.2-99.6% without).  
 For the diagnosis of type 1 or type 2 myocardial infarction performance improved in all 
patients, although the PPV and specificity remained lower in those with renal impairment 
(65.7%, 95% CI 61.0-70.3% and 78.0%, 95% CI 74.8-81.2% respectively), compared to those 
with normal renal function (77.5%, 95% CI 74.4-80.5% and 95.2%, 95% CI 94.4-95.9% 
respectively; Supplementary Table 6).  
Renal impairment and risk of type 1 myocardial infarction or cardiac death at 1 year 
Using Cox regression modeling, adjusted for age, sex, diabetes mellitus, hypertension, 
established ischemic heart disease, and cardiac troponin, we confirmed that renal impairment 
was an independent risk factor for subsequent type 1 myocardial infarction or cardiac death in 
the year following presentation (Supplementary Figure 2). This model independently 
confirmed that the risk of major cardiac events increased once the eGFR fell below 
60mL/min/1.73m2.
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Cardiac troponin risk stratifies patients with normal and impaired renal function 
For all patients, subsequent type 1 myocardial infarction or cardiac death at 1 year was more 
frequent with increasing cardiac troponin concentrations (Figure 2). Irrespective of the index 
diagnosis, in patients with any cardiac troponin concentration >99th centile the 1-year risk of 
subsequent type 1 myocardial infarction or cardiac death was greater in those with renal 
impairment compared to those without (24% vs. 10%, adjusted HR 2.19 [95% CI 1.54-3.11];
Table 3). Where cardiac troponin concentrations remained <5ng/L on serial testing, cardiac 
events at 1 year were uncommon in patients with or without renal impairment (2% vs. 0.4%, 
adjusted HR 2.49 [95% CI 0.58-10.71]). Patients with renal impairment and cardiac troponin 
concentrations QJ/EXW99th centile had a similar event rate to those with normal renal 
function and cardiac troponin concentrations >99th centile (7% and 10%, respectively).  
Increasing cardiac troponin concentrations below the 99th centile were associated with a 
greater risk of subsequent type 1 myocardial infarction or cardiac death at 1 year, after 
adjustment for age, sex, established ischemic heart disease, diabetes mellitus or hypertension 
(Figure 3). For every doubling of cardiac troponin concentration in those with renal impairment, 
risk of cardiac events increased more than two-fold (HR 2.62, 95% CI 2.09-3.14) compared to a 
more modest increase in those with normal renal function (HR 1.42, 95% CI 1.09-1.75). 
Discussion
In this large, prospective cohort of consecutive patients, we assessed the utility of high-
sensitivity cardiac troponin I testing to risk stratify and diagnose patients with suspected acute 
coronary syndrome who have renal impairment. We make several relevant observations for 
clinical practice. First, high-sensitivity cardiac troponin I concentrations <5ng/L at presentation 
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identified patients who were at low risk of myocardial infarction or cardiac death at 30 days 
regardless of renal function. However, fewer than 1 in 5 with renal impairment were identified as 
low risk, compared to more than half of those with normal renal function. Second, patients with 
renal impairment were more than twice as likely to have cardiac troponin concentrations >99th
centile. Here, the PPV and specificity for type 1 myocardial infarction were lower than for those 
with normal renal function. However, 1 in 4 patients with renal impairment had an index 
diagnosis of type 1 myocardial infarction, and this remained the most common cause of elevated
cardiac troponin concentrations in this group. Third, irrespective of the diagnosis, patients with 
cardiac troponin concentrations >99th centile and renal impairment had a 2-fold greater risk of 
subsequent type 1 myocardial infarction or cardiac death at 1 year. Finally, whilst increasing 
cardiac troponin concentrations <99th centile independently predicted subsequent cardiac events 
in all patients, for an equivalent increase in concentration, patients with renal impairment had 
twice the risk of a major cardiac event compared to those with normal renal function. Together 
these findings suggest that high-sensitivity cardiac troponin testing may improve the risk 
stratification of patients with suspected acute coronary syndrome and renal impairment by 
identifying both low risk patients who could avoid hospitalization, and high-risk patients who 
may benefit from further investigation and therapies.  
 Our study has a number of strengths. We prospectively identified all consecutive patients 
without selection presenting to both secondary and tertiary care hospitals, including patients 
admitted out-of-hours. Moreover, we included patients with all degrees of renal impairment 
including those with a severe reduction in eGFR or on dialysis, a group often excluded from 
diagnostic studies.27, 28 Thus, we consider our findings to be both representative and 
generalizable.
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Our findings in those patients with renal impairment and cardiac troponin concentrations 
<5ng/L at presentation support the use of this approach for risk stratification across all patients. 
Our analysis was conservative using a composite primary outcome that included cardiac events
at 30 days. The diagnostic sensitivity of 98.9% in patients with renal impairment would be 
considered by most as evidence that this approach could be safely applied in practice. Utilizing 
this threshold would potentially miss two index events in 904 consecutive patients with renal 
impairment. Indeed, a cardiac troponin concentration <5ng/L was associated with just a 2% risk 
of subsequent type 1 myocardial infarction or cardiac death in these patients at 1 year. Whilst 
this approach to risk stratification appears safe, it is clearly less effective in those with renal 
impairment, identifying fewer than 1 in 5 patients as low-risk compared to more than half of 
those with normal renal function. This observation likely reflects the higher prevalence of shared 
risk factors, pre-existing or unrecognized cardiovascular disease, or direct cardiac injury by 
uremic proteins in patients with renal impairment. 
 Our data add to those of others who have evaluated the effectiveness of high-sensitivity 
cardiac troponins for the diagnosis of myocardial infarction.16, 28-31 However, the majority of 
studies have included selected patients, not examined those with renal impairment separately, or 
have adjudicated outcomes using contemporary assays. A strength of our analysis is that all 
diagnoses and outcomes were adjudicated using the high-sensitivity assay. In keeping with
previous studies, the specificity of high-sensitivity cardiac troponin at the 99th centile for a 
diagnosis of type 1 myocardial infarction was reduced in patients with renal impairment.26 When 
considering the clinical utility of this diagnostic test, a reduction in PPV from 60% to 47% is 
arguably modest. One approach to improve specificity would be to use higher diagnostic 
thresholds in those with renal impairment.28, 32 However, this approach assumes that all grades of 
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renal impairment are equivalent, and implies to clinicians that small increases in cardiac troponin 
concentration are less important or are unrelated to cardiovascular risk in patients with renal 
impairment. Our analysis from a cohort of consecutive patients with the full spectrum of renal
function, demonstrates that patients with renal impairment who have elevated cardiac troponin 
concentrations have twice the risk of a major cardiac event than those with normal renal 
function. Furthermore, increases in cardiac troponin concentration within the normal reference 
range are a stronger predictor of cardiac events in patients with renal impairment, likely 
reflecting the higher burden of risk factors and cardiovascular disease in these patients. So whilst 
higher thresholds might improve diagnostic accuracy, there is a risk this approach may be falsely 
reassuring to clinicians.    
Renal impairment is associated with poor outcomes. In a recent study, renal impairment, 
defined as any reduction in eGFR, was responsible for 4% of all deaths worldwide, where more 
than half were a consequence of cardiovascular disease.33 Our data confirm this excess risk in 
patients with suspected acute coronary syndrome, but importantly suggest that cardiac troponin 
may be used to improve the risk stratification of these patients. Interestingly, we have shown that
patients with renal impairment in whom myocardial infarction has been excluded have a similar 
incident cardiovascular risk to those with myocardial injury or infarction who have normal renal 
function. Furthermore, we demonstrate a 2-fold increase in cardiovascular risk for every 
doubling of cardiac troponin in patients with renal impairment compared to those with normal 
renal function. This observation supports those who suggest elevations in cardiac troponin 
concentrations in kidney disease reflect underlying cardiovascular disease, rather than impaired 
renal clearance.12
 There is often a disparity in the use of common, evidence-based treatments or 
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interventions in patients with renal impairment.34 Far from this ‘therapeutic nihilism’ in the face 
of poor outcomes,34 high-sensitivity cardiac troponin could be used to improve the targeting of
therapy to this vulnerable and high-risk group of patients. Here, fewer than 30% of patients with 
renal impairment were prescribed aspirin, a blocker of the renin-angiotensin system or a statin.
Whether we can improve outcomes in this high-risk group of patients through increasing the use 
of these preventative therapies should be the urgent focus of future clinical studies.   
We recognize some limitations to our study. Only 15% of patients with reduced eGFR 
had severe renal impairment, with just 13 patients (1%) on dialysis,  so caution must be taken 
when interpreting these results in this group of patients. The study was conducted in a 
predominantly Caucasian population (93%), therefore further evaluation in more diverse 
populations would be of interest. Similarly, our findings are limited to a single high-sensitivity 
cardiac troponin I assay and cannot be extrapolated to other assays.32 Furthermore, clinical 
management decisions were made using a contemporary assay and therefore it is possible that a
small number of patients only identified by the high-sensitivity assay may have experienced 
worse outcomes as myocardial injury was not recognized by their treating clinician. However, 
this limitation affected all patients, and therefore does not impact the validity of our comparison 
between those with and without renal impairment. We classified patients based on a single 
estimate of renal function, and it is unclear whether those with renal impairment had acute 
kidney injury or chronic kidney disease. Both are associated with future cardiovascular risk.1, 35
However, our approach is consistent with clinical practice where renal function and cardiac 
troponin are measured concurrently and treatment decisions are largely based on measures of 
renal function at the time of presentation.  
In conclusion, high-sensitivity cardiac troponin I may improve the risk stratification of 
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patients with suspected acute coronary syndrome who have renal impairment by identifying low 
risk patients who could avoid hospitalization, and high-risk patients who may benefit from 
further investigation and therapies.  
Sources of Funding
AA is supported by a Research Fellowship from Chest Heart and Stroke Scotland (15/A163). 
ARC is supported by a Project Grant and a Fellowship (PG/15/51/31596, FS/16/75/32533) from 
the British Heart Foundation (BHF). NH is supported by a BHF Intermediate Basic Science 
Research Fellowship (FS/16/36/32205). DEN is the recipient of a Wellcome Trust Senior 
Investigator Award (WT103782AIA). NLM and DEN are supported by the Butler Senior 
Research Fellowship (FS/16/14/32023) and Chair (CH/09/002) awards from the BHF. ND is 
supported by a BHF Intermediate Clinical Research Fellowship (FS/13/30/29994). 
Disclosures
Drs Anand, Shah and Chapman have received honoraria from Abbott Diagnostics. Prof Mills has 
acted as a consultant for Abbott Diagnostics, Beckman-Coulter, Roche, and Singulex. All other 
authors report no conflicts. 
References
1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, 
Matsushita K and Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, 
mechanisms, and prevention. Lancet. 2013;382:339-352. DOI: 10.1016/S0140-6736(13)60595-4. 
2. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, 
Woodward M, Levey AS, de Jong PE, Coresh J and Gansevoort RT. Association of estimated 
glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general 
population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081. DOI: 
10.1016/S0140-6736(10)60674-5. 
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.030320
18
3. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, 
Gansevoort RT, Chronic Kidney Disease Prognosis C, van der Velde M, Matsushita K, Coresh J, 
Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt 
KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, 
Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen 
K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra 
N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B and Manley T. Lower 
estimated glomerular filtration rate and higher albuminuria are associated with all-cause and 
cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney 
Int. 2011;79:1341-1352. DOI: 10.1038/ki.2010.536. 
4. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos 
MC, Wiviott SD, Acute Coronary T and Intervention Outcomes Network r. Use of evidence-
based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-
ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report 
from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes 
Network registry. Circulation. 2010;121:357-365. DOI: 
10.1161/CIRCULATIONAHA.109.865352. 
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White 
HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM and 
Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial 
infarction. New Engl J Med. 2004;351:1285-1295.  
6. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR and Berger PB. The 
impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary 
interventions. J Am Coll Cardiol. 2002;39:1113-1119.  
7. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, Chapman AR, 
Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker AG, Reid A, Gray AJ, 
Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL and High Si. High-sensitivity 
cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort 
study. Lancet. 2015;386:2481-2488. DOI: 10.1016/S0140-6736(15)00391-8. 
8. Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, 
Andrews J, Tan S, Cheng SF, D'Souza M, Orme K, Strachan FE, Nestelberger T, Twerenbold R, 
Badertscher P, Reichlin T, Gray A, Shah ASV, Mueller C, Newby DE and Mills NL. 
Comparison of the Efficacy and Safety of Early Rule-Out Pathways for Acute Myocardial 
Infarction. Circulation. 2017;135:1586-1596. DOI: 10.1161/CIRCULATIONAHA.116.025021. 
9. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, Burge 
T, Machler P, Corbiere S, Grimm K, Gimenez MR, Puelacher C, Shrestha S, Flores Widmer D, 
Fuhrmann J, Hillinger P, Sabti Z, Honegger U, Schaerli N, Kozhuharov N, Rentsch K, Miro O, 
Lopez B, Martin-Sanchez FJ, Rodriguez-Adrada E, Morawiec B, Kawecki D, Ganovska E, 
Parenica J, Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S, Reichlin T and 
Mueller C. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial 
Infarction Using High-Sensitivity Cardiac Troponin I. Circulation. 2017;135:1597-1611. DOI: 
10.1161/CIRCULATIONAHA.116.025661. 
10. Haaf P, Drexler B, Reichlin T, Twerenbold R, Reiter M, Meissner J, Schaub N, Stelzig C, 
Freese M, Heinzelmann A, Meune C, Balmelli C, Freidank H, Winkler K, Denhaerynck K, 
Hochholzer W, Osswald S and Mueller C. High-sensitivity cardiac troponin in the distinction of 
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.030320
19
acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation.
2012;126:31-40. DOI: 10.1161/CIRCULATIONAHA.112.100867. 
11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint 
ESCAAHAWHFTFftUDoMI, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson 
P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, 
Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, 
Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen 
MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood 
D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, 
Parkhomenko AN, Vasilieva EJ and Mendis S. Third universal definition of myocardial 
infarction. Circulation. 2012;126:2020-2035. DOI: 10.1161/CIR.0b013e31826e1058. 
12. deFilippi CR and Herzog CA. Interpreting Cardiac Biomarkers in the Setting of Chronic 
Kidney Disease. Clin Chem. 2017;63:59-65. DOI: 10.1373/clinchem.2016.254748. 
13. Apple FS, Murakami MM, Pearce LA and Herzog CA. Predictive value of cardiac 
troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941-
2945.
14. Apple FS, Ler R and Murakami MM. Determination of 19 cardiac troponin I and T assay 
99th percentile values from a common presumably healthy population. Clin Chem.
2012;58:1574-1581. DOI: 10.1373/clinchem.2012.192716. 
15. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, 
Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby 
DE and Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial 
infarction in women: prospective cohort study. BMJ. 2015;350:g7873. DOI: 10.1136/bmj.g7873. 
16. Neumann JT, Sorensen NA, Ojeda F, Schwemer T, Lehmacher J, Gonner S, Jarsetz N, 
Keller T, Schaefer S, Renne T, Landmesser U, Clemmensen P, Makarova N, Schnabel RB, 
Zeller T, Karakas M, Pickering JW, Than M, Parsonage W, Greenslade J, Cullen L, Westermann 
D and Blankenberg S. Immediate Rule-Out of Acute Myocardial Infarction Using 
Electrocardiogram and Baseline High-Sensitivity Troponin I. Clin Chem. 2017;63:394-402. DOI: 
10.1373/clinchem.2016.262659. 
17. Sandoval Y, Smith SW, Shah AS, Anand A, Chapman AR, Love SA, Schulz K, Cao J, 
Mills NL and Apple FS. Rapid Rule-Out of Acute Myocardial Injury Using a Single High-
Sensitivity Cardiac Troponin I Measurement. Clin Chem. 2017;63:369-376. DOI: 
10.1373/clinchem.2016.264523. 
18. Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, Paterson E, 
MacLeod M, Graham C, Walker S, Denvir MA, Fox KA and Newby DE. Implementation of a 
sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with 
suspected acute coronary syndrome. JAMA. 2011;305:1210-1216. DOI: 10.1001/jama.2011.338. 
19. Mills NL, Lee KK, McAllister DA, Churchhouse AM, MacLeod M, Stoddart M, Walker 
S, Denvir MA, Fox KA and Newby DE. Implications of lowering threshold of plasma troponin 
concentration in diagnosis of myocardial infarction: cohort study. BMJ. 2012;344:e1533. DOI: 
10.1136/bmj.e1533. 
20. Shah AS, Newby DE and Mills NL. High sensitivity cardiac troponin in patients with 
chest pain. BMJ. 2013;347:f4222. DOI: 10.1136/bmj.f4222. 
21. Chin CW, Shah AS, McAllister DA, Joanna Cowell S, Alam S, Langrish JP, Strachan 
FE, Hunter AL, Maria Choy A, Lang CC, Walker S, Boon NA, Newby DE, Mills NL and Dweck 
MR. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic 
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.030320
20
response and adverse outcomes in patients with aortic stenosis. Eur Heart J. 2014;35:2312-2321. 
DOI: 10.1093/eurheartj/ehu189. 
22. Shah AS, Chin CW, Vassiliou V, Cowell SJ, Doris M, Kwok TC, Semple S, Zamvar V, 
White AC, McKillop G, Boon NA, Prasad SK, Mills NL, Newby DE and Dweck MR. Left 
ventricular hypertrophy with strain and aortic stenosis. Circulation. 2014;130:1607-1616. DOI: 
10.1161/CIRCULATIONAHA.114.011085. 
23. Froissart M, Rossert J, Jacquot C, Paillard M and Houillier P. Predictive performance of 
the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal 
function. J Am Soc Nephrol. 2005;16:763-773.  
24. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, 
Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby DE and Mills NL. Sensitive 
troponin assay and the classification of myocardial infarction. Am J Med. 2015;128:493-501 
e493. DOI: 10.1016/j.amjmed.2014.10.056. 
25. Apple FS, Collinson PO and Biomarkers ITFoCAoC. Analytical characteristics of high-
sensitivity cardiac troponin assays. Clin Chem. 2012;58:54-61. DOI: 
10.1373/clinchem.2011.165795. 
26. Brown L, Cai T and Dasgupta A. Interval Estimation for a Binomial Proportion. Stat Sci. 
2001;16:101-133. 
27. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, 
Moehring B, Fischer C, Meller B, Wildi K, Freese M, Stelzig C, Mosimann T, Reiter M, Mueller 
M, Hochgruber T, Sou SM, Murray K, Minners J, Freidank H, Osswald S and Mueller C. Risk 
stratification in patients with acute chest pain using three high-sensitivity cardiac troponin 
assays. Eur Heart J. 2014;35:365-375. DOI: 10.1093/eurheartj/eht218. 
28. Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, Walukiewicz A, 
Gugala M, Krivoshei L, Marti N, Moreno Weidmann Z, Hillinger P, Puelacher C, Rentsch K, 
Honegger U, Schumacher C, Zurbriggen F, Freese M, Stelzig C, Campodarve I, Bassetti S, 
Osswald S and Mueller C. Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays 
for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction. 
Circulation. 2015;131:2041-2050. DOI: 10.1161/CIRCULATIONAHA.114.014245. 
29. Carlton E, Greenslade J, Cullen L, Body R, Than M, Pickering JW, Aldous S, Carley S, 
Hammett C, Kendall J, Keevil B, Lord S, Parsonage W and Greaves K. Evaluation of High-
Sensitivity Cardiac Troponin I Levels in Patients With Suspected Acute Coronary Syndrome. 
JAMA Cardiol. 2016;1:405-412. DOI: 10.1001/jamacardio.2016.1309. 
30. Goorden SM, van Engelen RA, Wong LS, van der Ploeg T, Verdel GJ and Buijs MM. A 
novel troponin I rule-out value below the upper reference limit for acute myocardial infarction. 
Heart. 2016;102:1721-1727. DOI: 10.1136/heartjnl-2015-308667. 
31. Stacy SR, Suarez-Cuervo C, Berger Z, Wilson LM, Yeh HC, Bass EB and Michos ED. 
Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: 
a systematic review. Ann Intern Med. 2014;161:502-512. DOI: 10.7326/M14-0746. 
32. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger 
MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, 
Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, 
Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, 
Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, 
Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis 
Zamorano J and Management of Acute Coronary Syndromes in Patients Presenting without 
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.030320
21
Persistent STSEotESoC. 2015 ESC Guidelines for the management of acute coronary syndromes 
in patients presenting without persistent ST-segment elevation: Task Force for the Management 
of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation 
of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. DOI: 
10.1093/eurheartj/ehv320. 
33. Thomas B, Matsushita K, Abate KH, Al-Aly Z, Arnlov J, Asayama K, Atkins R, Badawi
A, Ballew SH, Banerjee A, Barregard L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, 
Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, 
Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, 
Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, 
Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, 
Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HM, Mendoza W, Metoki H, 
Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-
Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schottker B, 
Shankar A, Shlipak M, Silva DA, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock 
DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki ME, Naghavi M, Forouzanfar 
MH, Murray CJ, Coresh J, Vos T, Global Burden of Disease GFRC, Consortium CKDP and 
Global Burden of Disease Genitourinary Expert G. Global Cardiovascular and Renal Outcomes 
of Reduced GFR. J Am Soc Nephrol. 2017, 10.1681/ASN.2016050562. DOI: 
10.1681/ASN.2016050562. 
34. Gupta R, Birnbaum Y and Uretsky BF. The renal patient with coronary artery disease: 
current concepts and dilemmas. J Am Coll Cardiol. 2004;44:1343-1353. DOI: 
10.1016/j.jacc.2004.06.058. 
35. Odutayo A, Wong CX, Farkouh M, Altman DG, Hopewell S, Emdin CA and Hunn BH. 
AKI and Long-Term Risk for Cardiovascular Events and Mortality. J Am Soc Nephrol. 
2017;28:377-387. DOI: 10.1681/ASN.2016010105.  by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.030320
22
Table 1. Cohort characteristics in all patients and stratified by renal function
All patients
(n=4,726)
H*)5mL/min/1.73m2
(n=3,822)
eGFR <60 mL/min/1.73m2
(n=904)
Age (years) 64 (16) 61 (16) 77 (11)
Male 2,670 (56%) 2,236 (59%) 434 (48%)
Renal Function
&UHDWLQLQHȝPRO/ 89 (53) 75 (13) 151 (96)
eGFR (mL/min/1.73m2) 82 (26) 91 (18) 43 (13)
Presenting complaint
Chest pain 3,923 (83%) 3,264 (85%) 659 (73%)
Dyspnea 265 (6%) 164 (4%) 101 (11%)
Palpitations 126 (3%) 106 (3%) 20 (2%)
Syncope 173 (4%) 112 (3%) 61 (7%)
Past medical history
Smoker 847 (18%) 765 (20%) 80 (9%)
Diabetes mellitus 667 (14%) 431 (11%) 236 (26%)
Hyperlipidemia 1,122 (24%) 845 (22%) 277 (31%)
Hypertension 1,393 (29%) 1,015 (27%) 378 (42%)
Ischemic heart disease 1,391 (29%) 1,009 (26%) 382 (42%)
Myocardial infarction 796 (17%) 597 (16%) 199 (22%)
Stroke 337 (7%) 228 (6%) 109 (12%)
Previous revascularization
Percutaneous coronary intervention 447 (9%) 367 (10%) 80 (9%)
Coronary artery bypass grafting 245 (5%) 164 (4%) 83 (9%)
Admission drugs
Aspirin 926 (20%) 685 (18%) 241 (27%)
Clopidogrel 336 (7%) 247 (6%) 89 (10%)
Dual antiplatelet therapy 157 (3%) 127 (3%) 30 (3%)
ACE-inhibitor or ARB 961 (20%) 709 (19%) 252 (28%)
Beta-blocker 772 (16%) 565 (15%) 207 (23%)
Statin 1,123 (24%) 839 (22%) 284 (31%)
Oral anticoagulant 211 (4%) 148 (4%) 63 (7%)
Cardiac troponin I concentration
At presentation (ng/L) 5 (217) 4 (211) 17 (652)
At peak (ng/L) 9 (360) 6 (336) 27 (7167)
Less than 5ng/L at presentation 2301 (49%) 2144 (56%) 157 (17%)
Above 99th centile at presentation 938 (20%) 578 (15%) 360 (40%)
Above 99th centile on serial testing* 789 (36%) 519 (31%) 270 (54%)
Electrocardiogram
Ischemic appearance 816 (17%) 588 (15%) 228 (25%)
ST-segment depression 302 (6%) 210 (5%) 92 (10%)
Bundle branch block 278 (6%) 173 (5%) 105 (12%)
T-wave inversion 515 (11%) 404 (11%) 111 (12%)
Hemodynamic parameters
Heart rate (beats per minute) 82 (23) 81 (22) 84 (28)
Systolic blood pressure (mmHg) 138 (26) 139 (25) 135 (31)
Hospital utilization
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Length of hospital stay (days) 0.7 (0.22.4) 0.6 (0.21.8) 1.8 (0.76.1)
Discharged within 6 hours 1519 (32%) 1395 (36%) 124 (14%)
Adjudicated index diagnosis 
Type 1 myocardial infarction 651 (14%) 445 (12%) 206 (23%)
Type 2 myocardial infarction 173 (4%) 108 (3%) 65 (7%)
Myocardial injury 301 (6%) 160 (4%) 141 (16%)
Values are number (%) or mean (SD) or median (interquartile range) 
Abbreviations: eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme; 
ARB = angiotensin receptor blocker
*Percentages based on numbers with serial sampling (n=2,193) 
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Table 2. Diagnostic performance of risk stratification and diagnostic thresholds stratified by 
renal function
H*)5P/PLQP2
(n=3,822)
eGFR <60mL/min/1.73m2
(n=904)
Risk stratfication threshold <5ng/L at presentation
Composite Not Composite Composite Not Composite
<5ng/L 7 2137 2 155
QJ/ 451 1227 222 525
Sensitivity 98.4 (97.299.4) 98.9 (97.599.9)
Specificity 63.5 (61.9–65.1) 22.8 (19.7–26.0)
Negative predictive value 99.7 (99.499.9) 98.4 (96.099.7)
Positive predictive value 26.9 (24.829.0) 29.7 (26.5–33.1)
Negative likelihood ratio 0.02 (0.010.05) 0.03 (0.000.11)
Positive likelihood ratio 2.7 (2.62.8) 1.3 (1.21.3)
Diagnostic threshold >99th centile
Type 1 MI No MI Type 1 MI No MI
>99th centile 440 265 203 203
th centile 5 3112 3 495
Sensitivity 98.8 (97.7–99.7) 98.3 (96.5–99.8)
Specificity 92.1 (91.293.0) 70.9 (67.574.2)
Negative predictive value 99.8 (99.699.9) 99.3 (98.4–99.8)
Positive predictive value 62.4 (58.865.9) 50.0 (45.254.8)
Negative likelihood ratio 0.01 (0.00.03) 0.02 (0.000.05)
Positive likelihood ratio 12.6 (11.314.2) 3.4 (3.03.8)
Data presented as 2x2 tables of patient numbers. Sensitivity, specificity, negative predictive value and 
positive predictive value are % (95% confidence intervals). The composite primary outcome for risk 
stratification comprises index type 1 myocardial infarction, or readmission with type 1 myocardial 
infarction or cardiac death at 30 days. The diagnostic threshold outcome is for index type 1 myocardial 
infarction.
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Table 3. Outcomes at 1 year stratified by peak cardiac troponin concentration and renal function 
Peak cardiac 
troponin
eGFR, 
mL/min/1.73m2
n Readmission 
with type 1 MI, 
or cardiac death
Adjusted 
hazard ratio 
(95% CI)
P-value All-cause 
mortality
Adjusted 
hazard ratio 
(95% CI)
P-value
<5ng/L H*)5 2,016 9 (0.4%) 1.00 31 (2%) 1.00eGFR <60 135 3 (2%) 2.49 0.22 5 (4%) 1.11 0.85
(0.58–10.71) (0.37–3.36)
5ng/L-
99th centile
H*)5 1,094 23 (2%) 1.00 88 (8%) 1.00
eGFR <60 356 25 (7%) 3.03 <0.001 61 (17%) 1.63 0.009
(1.61–5.71) (1.13–2.34)
>99th centile H*)5 712 71 (10%) 1.00 112 (16%) 1.00eGFR <60 413 98 (24%) 2.19 <0.001 165 (40%) 1.90 <0.001
(1.54–3.11) (1.44–2.52)
eGFR = Estimated glomerular filtration rate
Cox regression models adjusted for age, sex, established ischemic heart disease, diabetes and hypertension
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Figure Legends
Figure 1. A) Cardiac troponin I concentration at presentation stratified by renal function and B) 
adjudicated index diagnosis >99th centile stratified by renal function 
Figure 2. Cumulative incidence plot for a composite of readmission with type 1 myocardial 
infarction or cardiac death at 1 year stratified by troponin and renal function. Across all patients, 
the risk of readmission with type 1 myocardial infarction or cardiac death increased with cardiac 
troponin (HR 1.15 [95% CI 1.07-1.25] per doubling, p<0.001) and eGFR (HR 1.28 [95% CI 
1.15-1.41] per fall of 10mL/min/1.73m2, p<0.001) after adjustment for age, sex, established 
ischemic heart disease, diabetes, hypertension and a cardiac troponin:eGFR interaction term (see 
Supplementary Table 7 for detailed model). 
Figure 3. Cox regression models for readmission with type 1 myocardial infarction or cardiac 
death at 1 year per two-fold increase in cardiac troponin concentration below the 99th centile 
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Supplementary Table 1: Diagnostic Criteria 
 
 
Type 1 myocardial infarction 
 
Myocardial necrosis (any high-sensitivity cardiac 
troponin I concentration above sex-specific 99th centile 
upper reference limit) with rise and or fall in hs-cTnI 
concentration where serial testing was available AND 
symptoms OR signs of myocardial ischemia 
 
 
Type 2 myocardial infarction 
 
Myocardial necrosis (high-sensitivity cardiac troponin I 
concentration above sex-specific 99th centile upper 
reference limit) with rise and or fall in high-sensitivity 
cardiac troponin I concentration where serial testing was 
available AND symptoms OR signs of myocardial 
ischemia AND evidence of increased oxygen demand 
(e.g. tachyarrhythmia, hypertrophy) or reduced supply 
(e.g. hypotension or anemia) in context of alternative 
clinical diagnosis 
 
 
Myocardial injury 
 
Myocardial necrosis (high-sensitivity cardiac troponin I 
concentration above sex-specific 99th centile upper 
reference limit) without symptoms OR signs of 
myocardial ischemia in context of alternative clinical 
diagnosis  
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Supplementary Table 2 
 
eGFR <15 
mL/min/1.73m2 
(n=37) 
eGFR 15-29 
mL/min/1.73m2 
(n=102) 
eGFR 3059 
mL/min/1.73m2 
(n=765) 
eGFR ≥60 
mL/min/1.73m2 
(n=3,822) 
Age (years) 68 (15) 78 (11) 77 (10) 61 (16) 
Male 26 (70%) 55 (54%) 353 (46%) 2,236 (59%) 
     
Renal Function     
Creatinine (μmol/L) 528 (185) 224 (49) 123 (26) 75 (13) 
eGFR (mL/min/1.73m2) 10 (3) 24 (4) 47 (8) 91 (18) 
     
Presenting complaint     
Chest pain 21 (57%) 60 (59%) 578 (76%) 3,264 (85%) 
Dyspnea 4 (11%) 22 (22%) 75 (10%) 164 (4%) 
Palpitations 1 (3%) 1 (1%) 18 (2%) 106 (3%) 
Syncope 3 (8%) 9 (9%) 49 (6%) 112 (3%) 
     
Past medical history     
Smoker 5 (14%) 5 (5%) 72 (9%) 765 (20%) 
Diabetes mellitus 13 (35%) 32 (31%) 191 (25%) 431 (11%) 
Hyperlipidemia 8 (22%) 29 (28%) 240 (31%) 845 (22%) 
Hypertension 21 (57%) 35 (34%) 322 (42%) 1,015 (27%) 
Ischemic heart disease 14 (38%) 44 (43%) 324 (42%) 1,009 (26%) 
Myocardial infarction 8 (22%) 27 (26%) 164 (21%) 597 (16%) 
Stroke 3 (8%) 17 (17%) 89 (12%) 228 (6%) 
     
Previous revascularization     
Percutaneous intervention 0 (0%) 5 (5%) 75 (10%) 367 (10%) 
Coronary artery bypass grafting 6 (16%) 6 (6%) 71 (9%) 164 (4%) 
     
Admission drugs     
Aspirin 8 (22%) 23 (23%) 210 (27%) 685 (18%) 
Clopidogrel 3 (8%) 9 (9%) 77 (10%) 247 (6%) 
Dual antiplatelet therapy 2 (5%) 1 (1%) 27 (4%) 127 (2%) 
ACE-inhibitor or ARB 4 (11%) 21 (21%) 227 (30%) 709 (19%) 
Beta-blocker 6 (16%) 21 (21%) 180 (24%) 565 (15%) 
Statin 6 (16%) 30 (29%) 248 (32%) 839 (22%) 
Oral anticoagulant 1 (3%) 5 (5%) 57 (7%) 148 (4%) 
     
Cardiac troponin I concentration    
At presentation (ng/L) 49 (14–151) 41 (18122) 14 (642) 4 (211) 
At peak (ng/L) 242 (58–833) 54 (201491) 22 (7115) 6 (336) 
<5ng/L at presentation 2 (5%) 4 (4%) 151 (20%) 2144 (56%) 
>99th centile at presentation 23 (62%) 65 (64%) 272 (36%) 578 (15%) 
     
Electrocardiogram     
Ischemic appearance 13 (35%) 30 (29%) 185 (24%) 588 (15%) 
 
 
4 
ST-segment depression 8 (22%) 13 (13%) 71 (9%) 210 (5%) 
Bundle branch block 3 (8%) 17 (17%) 85 (11%) 173 (5%) 
T-wave inversion 5 (14%) 12 (12%) 94 (12%) 404 (11%) 
     
Hemodynamic parameters     
Heart rate (beats per minute) 87 (27) 88 (27) 83 (28) 81 (22) 
Systolic BP (mmHg) 144 (39) 127 (37) 136 (30) 139 (25) 
     
Hospital utilization     
Length of hospital stay (days) 2.7 (0.9–8.2) 5.1 (1.211.8) 1.3 (0.35.0) 0.6 (0.21.8) 
Discharged within 6 hours 6 (16%) 2 (2%) 116 (15%) 1395 (36%) 
     
Adjudicated index diagnosis     
Type 1 myocardial infarction 10 (27%) 29 (28%) 167 (22%) 445 (12%) 
Type 2 myocardial infarction 5 (14%) 10 (10%) 50 (7%) 108 (3%) 
Myocardial injury 11 (30%) 27 (26%) 103 (13%) 160 (4%) 
     
Values are number (%) or mean (SD) or median (interquartile range) 
Abbreviations: eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BP = blood 
pressure 
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Supplementary Table 3: Performance of the risk stratification threshold (<5ng/L) for index type 1 
myocardial infarction or readmission with type 1 myocardial infarction or cardiac death within 30 
days, and index type 1 or type 2 myocardial infarction or readmission with type 1 or 2 myocardial 
infarction or cardiac death within 30 days  
 
 eGFR ≥60mL/min/1.73m
2 
(n=3,822) 
 
 
eGFR <60mL/min/1.73m2 
(n=904) 
 
Composite including only type 1 MI 
 
 
 
 
 
 
 
  Composite Not Composite  Composite Not Composite 
 <5ng/L 7 2137  2 155 
 ≥5ng/L 451 1227  222 525 
    
Sensitivity 98.4 (97.299.4)  98.9 (97.599.9) 
Specificity 63.5 (61.9–65.1)  22.8 (19.7–26.0) 
Negative predictive value 99.7 (99.499.9)  98.4 (96.099.7) 
Positive predictive value 26.9 (24.829.0)  29.7 (26.5–33.1) 
 
 
Composite including type 1 or type 2 MI 
 
 
 
 
 
 
 
  Composite Not Composite  Composite Not Composite 
 <5ng/L 10 2134  2 155 
 ≥5ng/L 555 1123  285 462 
    
Sensitivity 98.1 (97.099.2)  99.1 (98.199.9) 
Specificity 65.5 (63.9–67.1)  25.2 (21.8–28.6) 
Negative predictive value 99.5 (99.299.8)  98.4 (96.099.7) 
Positive predictive value 33.1 (30.935.4)  38.2 (34.7–41.7) 
    
 
Data presented as 2x2 tables of patient numbers. Sensitivity, specificity, negative predictive value and positive predictive value are % (95% 
confidence intervals).  
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Supplementary Table 4: Diagnostic performance of the limit of detection (1.2ng/L) on presentation 
as a risk stratification threshold in patients with and without renal impairment  
 
 eGFR ≥60mL/min/1.73m
2 
(n=3,822) 
 
 
eGFR <60mL/min/1.73m2 
(n=904) 
 
Risk stratification threshold <1.9ng/L (LoD) 
 
 
 
 
 
 
 
  Composite Not Composite  Composite Not Composite 
 <1.2ng/L 3 625  0 19 
 ≥1.2ng/L 455 2739  224 661 
    
Sensitivity 99.2 (98.499.9)  99.8 (99.1100.0) 
Specificity 18.6 (17.3–19.9)  2.9 (1.7–4.1) 
Negative predictive value 99.4 (98.799.9)  97.5 (90.5100.0) 
Positive predictive value 14.3 (13.1–15.5)  25.3 (22.5–28.3) 
    
 
Data presented as 2x2 tables of patient numbers. Sensitivity, specificity, negative predictive value and positive predictive value are % 
(95% confidence intervals). The composite primary outcome for risk stratification comprises index type 1 myocardial infarction, or 
readmission with type 1 myocardial infarction or cardiac death at 30 days.  
 
 
 
 Supplementary Table 5: Sub-group analysis of the diagnostic performance of the 99th centile for a diagnosis of type 1 myocardial infarction 
 
 
  Type 1 MI (%) TP TN FP FN Sensitivity Specificity NPV PPV 
All Patients (n=4,726) 
         
eGFR≥60ml/min/1.73m2 445 (12) 440 3112 265 5 98.8 
(97.7-99.7) 
92.1 
(91.2-93.0) 
99.8 
(99.6-99.9) 
62.4 
(58.8-65.9) 
eGFR<60ml/min/1.73m2 206 (23) 203 495 203 3 98.3 
(96.5-99.8) 
70.9 
(67.5-74.2) 
99.3 
(98.4-99.8) 
50.0 
(45.2-54.8) 
Males (n=2,670) 
         
eGFR≥60ml/min/1.73m2 284 (13) 280 1843 109 4 98.4 
(97.0-99.7) 
94.4  
(93.495.4) 
99.8 
(99.5-99.9) 
71.9  
(67.476.3) 
eGFR<60ml/min/1.73m2 100 (23) 98 252 82 2 97.5 
(94.5-99.8) 
75.4 
(70.7-79.9) 
99.0 
(97.5-99.8) 
54.4 
(47.1-61.6) 
Females (n=2,056) 
         
eGFR≥60ml/min/1.73m2 161 (10) 160 1269 156 1 99.1 
(97.6-100.0) 
89.0 
(87.4-90.6) 
99.9 
(99.6-100.0) 
50.6 
(45.1-56.1) 
eGFR<60ml/min/1.73m2 106 (23) 105 243 121 1 98.6 
(96.4-100.0) 
66.7 
(61.9-71.5) 
99.4 
(98.1-100.0) 
46.5 
(40.0-53.0) 
≥65 years old (n=2,411) 
         
eGFR≥60ml/min/1.73m2 247 (15) 243 1186 190 4 98.2 
(96.5-99.6) 
86.2 
(84.3-88.0) 
99.6 
(99.2-99.9) 
56.1 
(51.4-60.7) 
eGFR<60ml/min/1.73m2 183 (23) 180 419 186 3 98.1 
(96.1-99.7) 
69.2 
(65.5-72.9) 
99.2 
(98.1-99.8) 
49.2 
(44.1-54.3) 
<65 years old (n=2,315) 
         
eGFR≥60ml/min/1.73m2 198 (9) 197 1926 75 1 99.2 
(98.0-100.0) 
96.2 
(95.4-97.0) 
99.9 
(99.8-100.0) 
72.3 
(66.9-77.5) 
eGFR<60ml/min/1.73m2 23 (20) 23 76 17 0 97.9 
(92.1-100.0) 
81.4 
(73.5-88.9) 
99.4 
(97.5-100.0) 
57.3 
(42.1-71.9) 
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Serial sampling on presentation (n=2,193) 
eGFR≥60ml/min/1.73m2 359 (21) 263 1210 122 96 73.2 
(68.6-77.7) 
90.8 
(89.2-92.3) 
92.6 
(91.1-94.0) 
68.3 
(63.5-72.8) 
eGFR<60ml/min/1.73m2 159 (32) 121 247 96 38 75.9 
(69.3-82.4) 
71.9 
(67.2-76.6) 
86.5 
(82.4-90.2) 
55.7 
(49.1-62.3) 
Serial sampling on repeat testing (n=2,193)         
eGFR≥60ml/min/1.73m2 359 (21) 354 1174 158 5 98.5 
(97.2-99.6) 
88.1 
(86.4-89.8) 
99.5 
(99.1-99.8) 
69.1 
(65.0-73.0) 
eGFR<60ml/min/1.73m2 159 (32) 156 236 107 3 97.8 
(95.5-99.7) 
68.8 
(63.8-73.6) 
98.5 
(96.7-99.6) 
59.3 
(53.3-65.1) 
>99th centile and  ≥20% delta change (n=2,193) 
        
eGFR≥60ml/min/1.73m2 359 (21) 294 1206 126 65 81.8 
(77.8-85.7) 
90.5 
(88.9-92.1) 
94.9 
(93.6-96.0) 
70.0 
(65.5-74.2) 
eGFR<60ml/min/1.73m2 159 (32) 125 268 75 34 78.4 
(72.0-84.7) 
78.1 
(73.6-82.4) 
88.6 
(84.8-91.9) 
62.4 
(55.7-69.0) 
 
Diagnostic threshold >99th centile tested against an outcome of index type 1 myocardial infarction. TP = true positives; TN = true negatives; FP = false positives; FN = false negatives; NPV = negative predictive value; PPV = 
positive predictive value. Metrics provided are % (95% confidence intervals). 
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Supplementary Table 6: Performance of the diagnostic threshold (99th centile) for index type 
1 myocardial infarction and index type 1 or type 2 myocardial infarction  
 
 eGFR ≥60mL/min/1.73m
2 
(n=3,822) 
 
 
eGFR <60mL/min/1.73m2 
(n=904) 
 
Type 1 MI 
 
 
 
 
 
 
 
  Type 1 MI No MI  Type 1 MI No MI 
 >99th centile 440 265  203 203 
 ≤99th centile 5 3112  3 495 
    
Sensitivity 98.8 (97.7–99.7)  98.3 (96.5–99.8) 
Specificity 92.1 (91.293.0)  70.9 (67.574.2) 
Negative predictive value 99.8 (99.699.9)  99.3 (98.4–99.8) 
Positive predictive value 62.4 (58.865.9)  50.0 (45.254.8) 
 
 
Type 1 or type 2 MI 
 
 
 
 
 
 
 
  Type 1 or 2 MI No MI  Type 1 or 2 MI No MI 
 >99th centile 547 158  267 139 
 ≤99th centile 6 3111  4 494 
    
Sensitivity 98.8 (97.9–99.6)  98.3 (96.8–99.6) 
Specificity 95.2 (94.495.9)  78.0 (74.881.2) 
Negative predictive value 99.8 (99.699.9)  99.1 (98.1–99.7) 
Positive predictive value 77.5 (74.480.5)  65.7 (61.070.3) 
    
 
Data presented as 2x2 tables of patient numbers. Sensitivity, specificity, negative predictive value and positive predictive value are % (95% 
confidence intervals). 
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Supplementary Table 7: Cox proportional hazard models for predictors of readmission with 
type 1 myocardial infarction or cardiac death up to 1 year (229 events) 
 
Variable Model 1 Model 2  Model 3 Model 4 Model 5 
Age per 10 year 
increase 
2.02*** 
(1.81-2.26) 
1.74*** 
(1.57-1.95) 
1.47*** 
(1.30-1.66) 
1.44*** 
(1.26-1.63) 
1.44*** 
(1.26-1.63) 
Male sex 1.56**  
(1.19-2.04) 
1.39* 
(1.06-1.82) 
1.52** 
(1.16-1.98) 
1.58** 
(1.18-2.11) 
1.57** 
(1.18-2.10) 
Cardiac troponin 
per doubling 
 1.22*** 
(1.19-1.26) 
1.20*** 
(1.17-1.24) 
1.20*** 
(1.16-1.23) 
1.15*** 
(1.07-1.25) 
eGFR per fall of  
10mL/min/1.73m2 
  1.22*** 
(1.15-1.29) 
1.23*** 
(1.15-1.30) 
1.28***  
(1.15-1.41) 
Previous IHD    1.32  
(1.00-1.75) 
1.32  
(1.00-1.75) 
Diabetes    1.36  
(0.99-1.87) 
1.37  
(1.00-1.88) 
Hypertension    0.86  
(0.65-1.14) 
0.87  
(0.66-1.16) 
Cardiac troponin: 
eGFR interaction 
    1.00  
(1.00-1.00) 
 
No significant difference between Model 4 and Model 5 by ANOVA (p=0.31) 
***p<0.001; **p<0.01; *p<0.05 
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Supplementary Figure 1: Study CONSORT diagram 
 
 
 
 
  
 
 
12 
Supplementary Figure 2: Cox regression modelling of the relationship between estimated 
glomerular filtration rate and the risk of subsequent type 1 myocardial infarction or cardiac 
death 
 
 
 
 
 
 
 
